DE
  • Home
  • About medac
  • Information for patients
  • Healthcare professionals
  • Products
  • Career opportunities
  • Media
  • medac Produktpalette

    medac’s complete range of products

    Here you can find an overview of all products offered by medac, listed alphabetically from A to Z. Please click on the respective medicinal product for more information.

    Use the quick search to look for a specific product.

    5-FU medac
    Ingredient
    5-fluorouracil
    5‑FU medac 500 mg

    50 mg/ml, concentrate for solution for injection (10 ml)

    PZN:
    03727369
    5-FU medac 1.000 mg

    50 mg/ml, concentrate for solution for injection (20 ml)

    PZN:
    03728044
    5-FU medac 5.000 mg

    50 mg/ml, concentrate for solution for injection (100 ml)

    PZN:
    03728156
    5-FU medac 10.000 mg

    50 mg/ml, concentrate for solution for injection (200 ml)

    PZN:
    04142441

    Mechanism of action

    5-fluorouracil in itself is a non-antineoplastic synthetic fluorinated  pyrimidine derivate. After metabolism, cell division is inhibited by the active metabolites 5-fluorouridine triphosphate (FUTP) and 5-fluorodeoxyuridine monophosphate (FdUMP).

    Known mechanism of action

    • Blockade of DNA synthesis (inhibition of thymidylate synthase by FdUMP)
    • Inhibition of RNA synthesis (faulty structuring of RNA by incorporation of FUTP)
    • DNA strand breaks following incorporation of 5‑fluorodeoxyuridine triphosphate (phosphorylated FdUMP) in DNA

    The inhibitory effects are particularly evident in cells that grow rapidly and thus absorb 5‑fluorouracil to a greater extent.

    Adrimedac® 2 mg/ml solution for infusion
    Ingredient
    Doxorubicin hydrochloride
    Adrimedac® 2 mg/ml solution for infusion 10 mg

    1 vial with 5 ml solution for infusion

    PZN:
    07698251
    Adrimedac® 2 mg/ml solution for infusion 50 mg

    1 vial with 25 ml solution for infusion

    PZN:
    07698297
    Adrimedac® 2 mg/ml solution for infusion 200 mg

    1 vial with 100 ml solution for infusion

    PZN:
    07698274

    Mechanism of action

    Adrimedac® 2 mg/ml solution for infusion has a cytotoxic effect, inhibiting DNA and RNA synthesis through several mechanisms: intercalation between DNA bases, inhibition of various enzymes such as topoisomerase II, helicase and DNA and RNA polymerases and formation of free oxygen radicals.

    BCG-medac
    Ingredient
    BCG bacteria seed RIVM
    1 x 1 vial

    with solvent and instillation set

    PZN:
    02736461
    1 x 3 vials

    with solvent and instillation set

    PZN:
    02736484

    Mechanism of action 

    Immunostimulant

    Bendamustin medac
    Ingredient
    Bendamustine hydrochloride
    Bendamustin medac 

    25 mg

    PZN:
    11314144
    Bendamustin medac 

    100 mg

    PZN:
    11314204

    Mechanism of action

    Bendamustin medac is an alkylating substance containing the active substance bendamustine hydrochloride. The alkalising effect of bendamustine hydrochloride is essentially based on the cross-linking of DNA single and double strands, which impairs the synthesis and repair of DNA.

    Particularities:

    Bendamustine induces more rapid and frequent DNA double strand breaks compared to melphalan and cyclophosphamide.

    Moreover, the repair of bendamustine-induced DNA strand breaks has been shown to be more difficult and slower compared to cyclophosphamide and carmustine.

    Another advantage is that bendamustine does not show any cross-resistance with other alkylating agents.

    Bicalutamid medac
    Ingredient
    Bicalutamide
    Bicalutamid medac 50 mg

    package contains 30 or 90 film-coated tablets

    PZN:
    01712493
    01712501
    Bicalutamid medac 150 mg

    package contains 30 or 90 film-coated tablets

    PZN:
    01712518
    01712524
    Bleomedac®
    Ingredient
    Lyophilised bleomycin sulphate
    1 vial

    1 vial contains 15,000 I.U. lyophilised bleomycin sulphate (1 x 1)

    PZN:
    02411351
    1 vial

    1 vial contains 30,000 I.U. lyophilised bleomycin sulphate (1 x 1)

    PZN:
    02411368

    Mechanism of action

    Bleomycin has a cytostatic effect because of its specific binding to DNA, where it causes strand breaks.

    After administration, bleomycin forms an active complex with copper (Cu2+) and thus passes through the cell membrane into the cell interior. When the copper splits off in the cell plasma, bleomycin binds to DNA in the nucleus. Activated by free oxygen radicals, it induces strand breaks in the DNA. The greatest susceptibility is shown in cells in the G2 and M phases of the cell cycle.

    Capecitabin medac film-coated tablets
    Ingredient
    Capecitabine
    CAPECITABINmedac 150mg

    60 film-coated tablets

    PZN:
    10002997
    CAPECITABINmedac 500mg

    120 film-coated tablets

    PZN:
    10003011

    Mechanism of action

    Capecitabine is an orally administered precursor (prodrug) of 5‑fluorouracil (5-FU) and is activated in a three-step process in the liver and tumour tissue.

    1. After rapid absorption in the gastrointestinal tract, capecitabine in the liver is first metabolised by hepatic carboxylesterase to 5’-deoxy-5-fluorocytidine (5’-DFCR).

    2. 5’-DFCR is then converted to 5’-deoxy-5-fluorouridine (5’-DFUR) by cytidine deaminase, principally located in the liver and tumour tissues.

    3. The final catalytic activation occurs by thymidine phosphorylase, which is expressed in the tumour tissue in greater quantity. This transforms the 5’-DFUR into 5‑FU, resulting in cytostatic action affecting the tumour tissue in particular.

    Carbomedac® 
    Ingredient
    Carboplatin
    1 vial with 15 ml concentrate

    contains 150 mg carboplatin (1 x 1)

    PZN:
    04172583
    1 vial with 45 ml concentrate

    contains 450 mg carboplatin (1 x 1)

    PZN:
    04172643
    1 vial with 600 ml concentrate

    contains 600 mg carboplatin (1 x 1)

    PZN:
    04172689

    Mechanism of action

    Carboplatin has biochemical properties similar to those of cisplatin, thus producing predominantly interstrand and intrastrand DNA crosslinks. Carboplatin exhibited comparable activity to cisplatin against a wide range of tumours regardless of implant site. Alkaline elution techniques and DNA binding studies have demonstrated the qualitatively similar modes of action of carboplatin and cisplatin. Like cisplatin, carboplatin induces changes in the superhelical structure of the DNA, consistent with a ‘DNA-shortening effect’.

    Carmustin Obvius
    Ingredient
    carmustine
    Carmustin Obvius 100 mg

    1 vial with 100 mg powder

    1 ampoule with 3 ml of solvent

    PZN:
    15613843
    Cecenu®
    Ingredient
    Lomustine
    1 original package with 20 capsules

    1 capsule contains 40 mg lomustine

    PZN:
    08768798

    Mechanism of action

    After oral administration, lomustine breaks down spontaneously, first into a chlorethyl diazonium ion and then into a chlorethyl carbonium ion. Its cytostatic effect is the result of the alkylation of the O6 of guanine by the chlorethyl carbonium ion. Bifunctional alkylation leads to DNA crosslinking and induces apoptosis.

    Your Contact
    medac GmbH
    Head Office
    Theaterstraße 6 22880 Wedel Germany
    Nach oben